Some studies have reported a higher proportion of triple-negative cancers (ER-, PR-, human epidermal growth factor receptor 2 (HER2)-) among interval cancers [7,10] and this increase is even higher if only the subset of true interval cancers is considered in comparison to screening-detected cancers [4]. The gene discussed is ESR1; the disease is cancer.